The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2015

Filed:

Mar. 18, 2009
Applicants:

Shirit Einav, Stanford, CA (US);

Jeffrey S. Glenn, Palo Alto, CA (US);

Wenjin Yang, Foster City, CA (US);

Hadas Dvory-sobol, Mountain View, CA (US);

Ingrid C. Choong, Palo Alto, CA (US);

Robert Mcdowell, San Francisco, CA (US);

Inventors:

Shirit Einav, Stanford, CA (US);

Jeffrey S. Glenn, Palo Alto, CA (US);

Wenjin Yang, Foster City, CA (US);

Hadas Dvory-Sobol, Mountain View, CA (US);

Ingrid C. Choong, Palo Alto, CA (US);

Robert McDowell, San Francisco, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A61K 31/33 (2006.01); A61K 38/21 (2006.01); A61K 31/497 (2006.01); A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/708 (2006.01); A61K 45/06 (2006.01); C07K 14/005 (2006.01);
U.S. Cl.
CPC ...
A61K 31/497 (2013.01); A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 31/708 (2013.01); A61K 45/06 (2013.01); C07K 14/005 (2013.01); C12N 2770/24222 (2013.01); G01N 2333/186 (2013.01); G01N 2500/02 (2013.01);
Abstract

Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3'UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. In an embodiment, the compounds can include clemizole or a clemizole analog, or a pharmaceutically acceptable salt, an isomer, a tautomer, or a prodrug thereof.


Find Patent Forward Citations

Loading…